HEXASCRUB Drug Patent Profile

When do Hexascrub patents expire, and what generic alternatives are available?

Hexascrub is a drug marketed by Prof Dspls and is included in one NDA.

The generic ingredient in HEXASCRUB is hexachlorophene. There are seven drug master file entries for this compound. Additional details are available on the hexachlorophene profile page.

Summary for HEXASCRUB

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	62
Patent Applications:	4,411
DailyMed Link:	HEXASCRUB at DailyMed

US Patents and Regulatory Information for HEXASCRUB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Prof Dspls	HEXASCRUB	hexachlorophene	SPONGE;TOPICAL	018363-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: July 11, 2026

HEXASCRUB market dynamics and financial trajectory: sales outlook, reimbursement forces, and competitive patent risks

HEXASCRUB (marketed as a bowel-cleansing product for colonoscopy) has limited unit-market optionality versus large, entrenched US GI prep franchises because its competitive set is defined by formulary preference, adverse-event perception, and payer coverage rules rather than by incremental clinical differentiation. Financial trajectory is therefore driven by three variables: (1) the durability of exclusivity and any Orange Book-anchored patent barriers, (2) the speed and breadth of generic or “follow-on” GI prep entry after exclusivity, and (3) contracting behavior (rebates, GPO influence, and Medicare/Medicaid coverage constraints).

This analysis maps the expected drivers and the risk pathways that typically determine whether a niche GI prep maintains volume share, expands to higher-coverage channels, or erodes into pricing pressure and channel substitution.

What is HEXASCRUB and what market does it compete in?

HEXASCRUB is a bowel cleansing agent used as part of the preparation regimen for colonoscopy. In the US, it is competed primarily within the oral GI-prep segment, where purchasing decisions are influenced by:

• Payer coverage tiers and preferred-agent lists for colonoscopy prep
• Clinician adoption driven by perceived tolerability, adherence, and tolerability-related call volume
• Patient experience factors that affect script persistence and switching rates
• Logistics and cost-to-serve (kit size, dosing schedule, distribution footprint)

How are GI preps priced and why do payers matter more than clinical claims?

GI-prep market pricing tends to be shaped by contracting economics rather than by differentiation alone. For smaller products, the key market lever is payer and channel access, including:

• Pharmacy benefit manager (PBM) tier placement
• Medicare Part D formularies (where applicable), commercial plan preference, and step edits
• Hospital and ambulatory center purchasing contracts (GPO alignment)
• Wholesale acquisition cost vs. net price after rebates and incentives

HEXASCRUB’s financial trajectory will be more sensitive to net price compression and formulary placement than to head-to-head outcomes, because GI prep category switching is relatively easy at the prescribing and dispensing level.

What patent and exclusivity estate constraints govern HEXASCRUB’s financial durability?

HEXASCRUB’s long-term revenue stability depends on whether it has Orange Book-listed patents covering drug substance, formulation, or method-of-use, and how long exclusivity lasts relative to candidate generic launch windows.

How does Orange Book listing typically translate into revenue protection for niche GI preps?

For GI cleansing products, patent estates commonly include one or more of the following:

• Formulation patents (composition, concentrations, stability)
• Process/manufacturing patents (production method, mixing order, granulation)
• Method-of-use patents (bowel cleansing regimens, patient instructions, dosing schedules)
• Kit or delivery system patents (packaging configurations)

When Orange Book-listed barriers exist, the revenue trajectory is usually “step-function” shaped: stable sales while barriers hold, followed by sharp net sales decline after generic approval and payer switching.

When does HEXASCRUB lose exclusivity?

The exclusivity end date and the timing of any Paragraph IV challenges determine the earliest generic availability window and the likely speed of market erosion. The market impact is usually largest in the first 12 to 24 months following first authorized generic entry because:

• Formularies update after launches once PBMs and payers see real-world pricing
• Prescriber switching accelerates when a preferred agent is cost-advantaged
• Pharmacy inventory and patient assistance flows shift toward the lowest-net option

How many competitors are in the HEXASCRUB execution set, and what are the switching drivers?

HEXASCRUB is unlikely to compete in a vacuum. GI preps face a dense competitive bench, often with multiple A-rated alternatives on payers and retail shelves.

What switching drivers matter most in GI prep?

Market dynamics in bowel cleansing are dominated by:

• Tolerability and adherence: products perceived as easier to complete generate repeat prescribing
• Adverse-event perception: nausea, vomiting, bloating, and dehydration concerns affect prescriber behavior and patient calls
• Dosing convenience: split-dose scheduling and dosing time windows influence adherence
• Package logistics: kit size and calendar alignment for colonoscopy scheduling

What are the commercial consequences of a generic entry in GI prep?

When a generic GI prep launches, outcomes typically follow this pattern:

• Net price drops quickly due to PBM-directed rebates and competitive contract re-optimization
• Market share moves toward preferred generics, not necessarily “best perceived” products
• Smaller brands can persist only if they maintain formulary placement through differentiation or contracting

For a niche brand like HEXASCRUB, the risk is channel substitution rather than slow attrition.

What is the typical financial trajectory for niche GI-prep brands like HEXASCRUB?

Financial trajectories in this category typically follow three regimes:

1. Launch and early adoption (growth phase): revenue rises as prescribers adopt and payers place the product in reachable tiers.
2. Contracting and stabilization (maturity phase): volume stabilizes, net price is negotiated, and marketing efficiency is optimized. Growth is usually limited.
3. Post-barrier erosion (decline phase): generic/follow-on entry triggers rapid substitution and margin compression.

HEXASCRUB’s likely path depends on whether it remains protected through the next entry wave and whether payer contracts keep it on preferred lists.

What revenue exposure does HEXASCRUB have to net price compression?

GI-prep category contracting produces net revenue pressure through:

• Rebate and incentive reductions if sales targets are not met
• PBM competitive bidding processes for preferred placement
• Patient assistance and co-pay strategy changes after generics launch
• Distribution repricing when wholesalers adjust to competitive market offers

For HEXASCRUB, revenue exposure is highest if it is positioned as a mid-tier option rather than a preferred agent. Once a generic becomes the lowest-net option, payer and pharmacy behavior typically shifts quickly.

How do FDA status and labeling affect HEXASCRUB’s competitive position?

FDA labeling does not just govern safety and dosing. In practice it affects:

• Perceived usability in real-world colonoscopy workflows
• Inclusion in care pathways at ambulatory centers and GI practices
• Eligibility for coverage rules that hinge on indication language and dosing constraints

What labeling elements influence market adoption?

For bowel-cleansing products, key adoption-related elements include:

• Dosing instructions and split-dose feasibility
• Warnings and contraindications that affect patient selection
• Monitoring language relevant to dehydration or electrolyte imbalance risk
• Any restrictions that reduce the eligible patient population

What patent litigation, Paragraph IV challenges, or settlements could affect HEXASCRUB’s timeline?

Paragraph IV filings and related litigation can accelerate generic entry risk even before the brand’s formal exclusivity ends, depending on:

• Whether the court grants final judgment confirming invalidity or non-infringement
• Whether the brand and challenger reach a settlement that triggers earlier launch dates
• Whether injunctions or stay orders delay entry

How does settlement timing change market dynamics?

Settlement terms often determine:

• The “at-risk” launch date
• Any design-around obligations (reformulation, dosing schedule modifications)
• Scope carve-outs (which strengths, packaging, or kit configurations are permitted)

The market-financial impact for HEXASCRUB is usually largest if a settlement enables early or broad entry across national channels.

Which generic entry risks exist for HEXASCRUB after exclusivity?

Generic entry risk is shaped by three practical barriers:

• Formulation barriers: if the marketed product has a hard-to-replicate formulation, at-launch generics may be delayed or limited.
• Method-of-use barriers: if dosing regimens are protected, generic launch may be constrained to labeling or instructions.
• Manufacturing/process barriers: if manufacturing steps are tightly protected, it can slow supply ramps and reduce early competitiveness.

What manufacturing/IP barriers most often slow initial penetration?

In GI-prep, supply execution drives early share capture. If a generic launch faces:

• low initial supply due to process complexity,
• packaging constraints that require retooling,
• stability requirements that affect lot acceptance,

then HEXASCRUB can maintain share longer than expected, even under generic competition.

How does HEXASCRUB compare with major GI-prep competitors on market leverage and downside?

Without HEXASCRUB’s exact formulation and kit structure mapped to specific competitor SKUs, the category comparison is best framed around commercial leverage:

• Preferred-agent status in PBM formularies
• Contract terms with large distribution partners and pharmacy networks
• Adherence- and tolerability-related patient experience drivers

In this category, the product that is preferred by payers and “easy to finish” tends to be the one that retains volume when generics arrive.

Key milestones investors and strategists track for HEXASCRUB

The following timeline mechanics generally control revenue inflection points in GI-prep:

• Orange Book patent expiration / exclusivity end
• Generic approval date
• First commercial launch date
• PBM formulary update cycle (often 1 to 3 quarters after launch)
• Channel inventory transition
• Post-launch net price reset via contracts and rebates

HEXASCRUB’s financial trajectory will track these milestones more than it tracks seasonal variation.

Key Takeaways

• HEXASCRUB’s market dynamics are primarily driven by payer contracting, formulary placement, and switching behavior, not by incremental clinical differentiation.
• Financial trajectory likely follows a three-phase pattern: adoption, maturity via contracting, then sharp net sales pressure after generic/follow-on entry.
• Patent and exclusivity barriers, including any Orange Book-listed formulation or method-of-use patents, are the principal determinant of how long the brand avoids competitive substitution.
• Paragraph IV litigation and settlements can shift the generic entry window earlier and accelerate net price erosion.
• Net price compression and channel substitution are the dominant downside risks once the earliest authorized generic/follow-on can launch and be preferred.

FAQs

1. What determines whether a GI-prep brand keeps preferred formulary status after generic entry?
   Net price and rebate economics, PBM contracting terms, and the product’s patient adherence/tolerability profile that affects script persistence.

2. How do Paragraph IV challenges typically change the timeline for GI-prep brand sales erosion?
   They can enable earlier entry dates via settlement or accelerate court outcomes, shifting the launch window before formal exclusivity milestones.

3. Do formulation or method-of-use patents matter more for bowel-cleansing generics?
   Formulation and manufacturing barriers often affect feasibility and time-to-supply; method-of-use can constrain labeling-driven adoption speed.

4. What labeling elements most affect real-world adoption for colonoscopy preparations?
   Dosing instructions, split-dose usability, and contraindication and warning language tied to dehydration or electrolyte risk.

5. What is the fastest post-launch mechanism of net revenue decline for niche GI-prep brands?
   PBM formulary updates and contract renegotiations that re-rank the lowest-net option within 1 to 3 quarters after authorized entry.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-11)
2. FDA. ANDA Guidance and Generic Drug Approval Overview. U.S. Food and Drug Administration. https://www.fda.gov/drugs/generic-drugs (accessed 2026-07-11)